IP Library Granted Patent US 9,517,246
Granted Patent B2
US 9,517,246 · App. 15/212,771 · Granted Dec 13, 2016

Chitosan derivatives for inactivation of endotoxins and surface protection of nanoparticles

Inventors: Yoon Yeo (West Lafayette, IN); Gaurav Bajaj (Lafayette, IN); Peisheng Xu (Lafayette, IN); Karen Liu (Lafayette, IN); Eun Jung Cho (West Lafayette, IN)
Assignee: PURDUE RESEARCH FOUNDATION
A61K31/722
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,517,246
App. No.
15/212,771
Granted
Dec 13, 2016
Kind
B2
Abstract

The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.

Claims (8)

1. An anti-tumor nanoparticle comprising a non-covalent, electrostatic complex between (1) a conjugate comprising a poly(amidoamine) dendrimer (PAMAM dendrimer) and an anti-tumor agent and (2) a zwitterionic chitosan derivative having an anhydride to amine (An/Am) ratio of 0.3 to 0.7, wherein (A) the zwitterionic chitosan derivative was synthesized by partial amidation of a chitosan with succinic anhydride, (B) the weight ratio of zwitterionic chitosan derivative to PAMAM dendrimer is greater than or equal to 1 but less than or equal to 4, and (C) the size of the anti-tumor nanoparticle is between 250 nm and about 500 nm.

2. The anti-tumor nanoparticle of claim 1 , wherein the PAMAM dendrimer is a generation 5 (G5) dendrimer.

3. A method of treating a tumor in a mammal, wherein the tumor has a weakly acidic microenvironment of pH 6.5 to 7.2, the method comprising parenterally administering to the mammal an effective amount of the anti-tumor nanoparticles of claim 1 .

4. A method of treating a tumor in a mammal, wherein the tumor has a weakly acidic microenvironment of pH 6.5 to 7.2, the method comprising parenterally administering to the mammal an effective amount of the anti-tumor nanoparticles of claim 2 .

5. An imaging nanoparticle comprising a non-covalent, electrostatic complex between (1) a conjugate comprising a poly(amidoamine) dendrimer (PAMAM dendrimer) and an imaging agent and (2) a zwitterionic chitosan derivative having an anhydride to amine (An/Am) ratio of 0.3 to 0.7, wherein (A) the zwitterionic chitosan derivative was synthesized by partial amidation of a chitosan with succinic anhydride, (B) the weight ratio of zwitterionic chitosan derivative to PAMAM dendrimer is greater than or equal to 1 but less than or equal to 4, and (C) the size of the imaging nanoparticle is between 250 nm and about 500 nm.

6. The imaging nanoparticle of claim 5 , wherein the PAMAM dendrimer is a generation 5 (G5) dendrimer.

7. A method of imaging a tumor in a mammal, wherein the tumor has a weakly acidic microenvironment of pH 6.5 to 7.2, the method comprising parenterally administering to the mammal an effective amount of the imaging nanoparticles of claim 5 .

8. A method of imaging a tumor in a mammal, wherein the tumor has a weakly acidic microenvironment of pH 6.5 to 7.2, the method comprising parenterally administering to the mammal an effective amount of the imaging nanoparticles of claim 6 .

Continuity (3)
Continuation 13628991 · Sep 27, 2012
Provisional Application 61539557 · Sep 27, 2011
Related Publication 20160324886A1 · Nov 10, 2016